PPARG and urinary bladder carcinoma: Recently, a study showed that three recurrent mutations, PPARγM280I, PPARγT475M and PPARγI290M, modify the conformation and structural dynamics of the protein, and subsequently affect the ligand binding domain of PPARγ, resulting in a change in protein activity in luminal bladder cancer 65.